ArticleFrontiers in microbiology2026
Rapid and high-sensitivity quantitative fluorescent immunoassay for detection of
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early and precise identification of Methods: The assay employs a sandwich immunoassay format, which utilizes carboxylated magnetic agarose microspheres for capture and time-resolved fluorescent microspheres for detection. It enables quantification of the KPC protein within approximately 1 h. The analytical performance of the assay was systematically evaluated, including its sensitivity, linear range, specificity and accuracy. Results: Under optimal experimental conditions, it exhibits a wide linear range (0.25-1000 ng/mL) and a low detection limit of 0.194 ng/mL, and shows no cross-reactivity with other common carbapenemases. Recovery rates in bacterial lysates ranged from 96.7 to 108.4%. Compared to a commercial immunochromatographic test, this method demonstrated superior sensitivity. Discussion: The primary advantage of this fluorescent immunoassay is its ability to achieve rapid, sensitive and quantitative detection of KPC, which addresses a key limitation of current qualitative methods. Its wide linear range and low detection limit enable precise monitoring of KPC expression level variations, offering a novel tool for the clinical assessment of bacterial resistance burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.